The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 1,501–1,600 of 4,628
Khedoe, P. P. S. J., Marges, E. R., Hiemstra, P. S., Ninaber, M. K., & Geelhoed, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01990 · Cited by 26
“, VEGF, fibroblast growth factor (FGF), and PDGF pathways (89).”
BackgroundRepurposing Nintedanib for Pathological Cardiac Remodeling and Dysfunction
Umbarkar, P., Singh, A. P., Tousif, S., Zhang, Q., Sethu, P., & Lal, H. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2021.105605 · Cited by 29
Hisata, S., Bando, M., Homma, S. A., Kataoka, K., Ogura, T., Izumi, S., Sakamoto, S., Watanabe, K., Saito, Y., Shimizu, Y., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.04.005 · Cited by 32
Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens
Testa, L. C., Julé, Y., Lundh, L., Bertotti, K., Merideth, M. A., O’Brien, K., Nathan, S. D., Venuto, D. C., El‐Chemaly, S., Malicdan, M. C. V., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.607720 · Cited by 24
“Pirfenidone and nintedanib are antifibrotic drugs approved by the Food and Drug Administration (FDA) as treatment for IPF, and lung transplantation may be performed in suitable candidates with severe disease (3, 4).”
BackgroundWu, W., Bonnet, S., Shimauchi, T., Toro, V., Grobs, Y., Romanet, C., Bourgeois, A., Vitry, G., Omura, J., Tremblay, È., et al. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217377 · Cited by 24
E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
Sharma, S., Watanabe, T., Nishimoto, T., Takihara, T., Mlakar, L., Nguyen, X.-X., Sanderson, M., Su, Y., Chambers, R. A., & Feghali‐Bostwick, C. A. (2021) · JCI Insight · doi:10.1172/jci.insight.144935 · Cited by 25
Kamp, J. C., Neubert, L., Stark, H., Hinrichs, J. B., Boekhoff, C., Seidel, A. D., Ius, F., Haverich, A., Gottlieb, J., Welte, T., et al. (2022) · Cells · doi:10.3390/cells11040664 · Cited by 27
Ye, Y., Hubbard, R., Li, G. H., Ho, S., Sing, C., Cheung, C. L., & Lam, D. C. L. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5421 · Cited by 27
Li, L., Chen, Y., & Shi, C. Q. (2022) · Bioengineered · doi:10.1080/21655979.2022.2036913 · Cited by 25
Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study
Singh, P. K., Behera, D., Gupta, S. S., Deep, A., Priyadarshini, S., & Padhan, P. (2022) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715221103402 · Cited by 25
Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
Zhang, T., Zhang, J., Lv, C., Li, H., & Song, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1059434 · Cited by 29
“In placebo-controlled, randomised phase 3 studies, pirfenidone and nitisinib effectively slowed disease progression, but did not improve survival or reverse pulmonary fibrosis (Lomas et al., 2012; King et al., 2014; Richeldi et al., 2014).”
BackgroundInhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
Ma, H., Heiden, J. A. V., Uttarwar, S., Xi, Y., N’Diaye, E.-N., LaCanna, R., Caplazi, P., Gierke, S., Moffat, J. G., Wolters, P. J., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00604-2022 · Cited by 30
Urteaga, M. B., Ruz, J. R., & González, M. S. (2022) · Radiología (English Edition) · doi:10.1016/j.rxeng.2022.10.009 · Cited by 40
Ji, H.-M., Dong, H., Lan, Y., Bi, Y., Gu, X., Han, Y., Yang, C., Cheng, M.-H., & Gao, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1089812 · Cited by 24
“However, neither of them provides a cure, and both of them are associated with several serious drugrelated side effects, including gastrointestinal events, rash and photosensitivity (Richeldi et al., 2014; Cottin and Maher, 2015; Zhang et al., 2019).”
BackgroundKhor, Y. H., Schulte, M., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., Ryerson, C. J., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.02163-2022 · Cited by 25
Self-citationPulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-γ)
Fusiak, T., Smaldone, G. C., & Condos, R. (2015) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2015.1221 · Cited by 23
Lin, C., Rezaee, F., Waasdorp, M., Shi, K., van der Poll, T., Borensztajn, K., & Spek, C. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6095 · Cited by 26
The changing treatment landscape in idiopathic pulmonary fibrosis
Costabel, U. (2015) · European Respiratory Review · doi:10.1183/09059180.00011414 · Cited by 25
Self-citationIwasawa, T., Kanauchi, T., Hoshi, T., Ogura, T., Baba, T., Gotoh, T., & Oba, M. S. (2015) · Japanese Journal of Radiology · doi:10.1007/s11604-015-0496-0 · Cited by 26
Treatment of Idiopathic Pulmonary Fibrosis
Carlos, W. G., Strek, M. E., Wang, T. S., Patel, H., Raghu, G., Wilson, K. C., & Thomson, C. C. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201510-713cme · Cited by 24
Self-citationEkström, M. P., & Hermansson, A. B. (2016) · Respirology · doi:10.1111/resp.12781 · Cited by 26
Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis
Fukihara, J., & Kondoh, Y. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1249854 · Cited by 27
Mäkelä, K., Hodgson, U., Piilonen, A. K., Kelloniemi, K., Bloigu, R., Sutinen, E., Salmenkivi, K., Rönty, M. J., Lappi‐Blanco, E., Myllärniemi, M., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001031 · Cited by 26
Safety of nintedanib before lung transplant: an Italian case series
Balestro, E., Solidoro, P., Parigi, P., Boffini, M., Lucianetti, A., & Rea, F. (2018) · Respirology Case Reports · doi:10.1002/rcr2.312 · Cited by 25
Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Arora, A., Bhuria, V., Hazari, P. P., Pathak, U., Mathur, S., Roy, B. G., Sandhir, R., Soni, R., Dwarakanath, B. S. R., & Bhatt, A. N. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00394 · Cited by 23
Maldonado, M., Buendía-Roldán, I., Vicens‐Zygmunt, V., Planas‐Cerezales, L., Molina‐Molina, M., Selman, M., & Pardo, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203779 · Cited by 24
Self-citationUtility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
Abe, M., Tsushima, K., Sakayori, M., Suzuki, K., Ikari, J., Terada, J., & Tatsumi, K. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s179427 · Cited by 25
The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice
Koyama, K., Goto, H., Morizumi, S., Kagawa, K., Nishimura, H., Sato, S., Kawano, H., Toyoda, Y., Ogawa, H., Homma, S. A., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0098oc · Cited by 25
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options
Trachalaki, A., Irfan, M., & Wells, A. U. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1822326 · Cited by 26
Interstitial lung disease: raising the index of suspicion in primary care
Zibrak, J. D., & Price, D. B. (2014) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2014.54 · Cited by 25
Kawano-Dourado, L. B., Kulkarni, T., Ryerson, C. J., Rivera‐Ortega, P., Baldi, B. G., Chaudhuri, N., Funke-Chambour, M., Hoffmann‐Vold, A., Johannson, K. A., Khor, Y. H., et al. (2024) · Thorax · doi:10.1136/thorax-2023-221148 · Cited by 28
Salisbury, M. L., Markin, C. R., Fadely, T. H., Guttentag, A. R., Humphries, S. M., Lynch, D. A., Kropski, J. A., & Blackwell, T. S. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0524oc · Cited by 23
Loganath, K., Craig, N. J., Barton, A. K., Joshi, S. S., Anagnostopoulos, C., Erba, P. A., Glaudemans, A. W. J. M., Saraste, A., Bucerius, J. A., Lubberink, M., et al. (2024) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2024.102106 · Cited by 29
Myllärniemi, M., Tikkanen, J., Hulmi, J. J., Pasternack, A. H., Sutinen, E., Rönty, M. J., Leppäranta, O., Ma, H., Ritvos, O., & Koli, K. M. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-170 · Cited by 24
Kreuter, M., Wälscher, J., & Behr, J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000408 · Cited by 24
Bahudhanapati, H., & Kass, D. J. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0079ed · Cited by 23
Gaffney, A. W., Steffie, W., Himmelstein, D. U., & McCormick, D. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3407-0 · Cited by 28
Zhang, E., Yang, Y., Zhang, J., Ding, G., Chen, S., Peng, C., Lavin, M. F., Yeo, A. J., Du, Z., & Shao, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7205 · Cited by 25
Nintedanib inhibits TGF-β-induced myofibroblast transdifferentiation in human Tenon's fibroblasts.
Lin, X., Wen, J., Liu, R., Gao, W., Qu, B., & Yu, M. (2018) · PubMed Central · Cited by 35
TRIM72 promotes alveolar epithelial cell membrane repair and ameliorates lung fibrosis
Cong, X., Nagre, N. N., Herrera, J., Pearson, A. C., Pepper, I., Morehouse, R., Ji, H., Jiang, D., Hubmayr, R. D., & Zhao, X. (2020) · Respiratory Research · doi:10.1186/s12931-020-01384-2 · Cited by 27
Kolonics-Farkas, A. M., Šterclová, M., Moğulkoç, N., Kuś, J., Hájková, M., Müller, V., Jovanović, D. M., Tekavec-Trkanjec, J., Littnerová, S., Hejduk, K., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-00978-5 · Cited by 24
Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality
Hyldgaard, C., Møller, J., & Bendstrup, E. M. (2020) · European Clinical Respiratory Journal · doi:10.1080/20018525.2020.1807682 · Cited by 29
“This group of patients mainly have a probable UIP pattern on HRCT, and they have the same disease course and response to antifibrotic therapy as those with a definite UIP pattern or a histopathological diagnosis confirming IPF [4].”
BackgroundHolland, A. E., Corte, T. J., Chambers, D. C., Palmer, A. J., Ekström, M. P., Glaspole, I., Goh, N. S. L., Hepworth, G., Khor, Y. H., Hoffman, M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040798 · Cited by 27
Sebastiani, M., Faverio, P., Manfredi, A., Cassone, G., Vacchi, C., Stainer, A., Pozzi, M. R., Salvarani, C., Pesci, A., & Luppi, F. (2020) · Biomedicines · doi:10.3390/biomedicines9010017 · Cited by 25
Deterding, R. R., Griese, M., Deutsch, G. H., Warburton, D., DeBoer, E. M., Cunningham, S., Clément, A., Schwerk, N., Flaherty, K. R., Brown, K. K., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00805-2020 · Cited by 30
Self-citationA mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease
Khor, Y. H., Saravanan, K., Holland, A. E., Lee, J. Y. T., Ryerson, C. J., McDonald, C. F., & Goh, N. S. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-86326-8 · Cited by 31
Cutolo, M., Gotelli, E., Montagna, P., Tardito, S., Paolino, S., Pizzorni, C., Sulli, A., Smith, V. M., & Soldano, S. (2021) · Arthritis Research & Therapy · doi:10.1186/s13075-021-02555-2 · Cited by 28
Miura, Y., Ohkubo, H., Niimi, A., & Kanazawa, S. (2021) · ERJ Open Research · doi:10.1183/23120541.00345-2021 · Cited by 27
Dempsey, T. M., Thao, V., Moriarty, J. P., Borah, B. J., & LIMPER, A. H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01811-0 · Cited by 25
Assassi, S., Distler, O., Allanore, Y., Ogura, T., Varga, J., Vettori, S., Crestani, B., Voß, F., Alves, M., Stowasser, S., et al. (2022) · ACR Open Rheumatology · doi:10.1002/acr2.11483 · Cited by 24
Self-citationDDR1 activation in macrophage promotes IPF by regulating NLRP3 inflammasome and macrophage reaction
Wang, H., Wen, Y., Wang, L., Wang, J., Chen, H., Chen, J., Guan, J., Xie, S., Chen, Q. P., Wang, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109294 · Cited by 23
Walking the path of treatable traits in interstitial lung diseases
Amati, F., Spagnolo, P., Ryerson, C. J., Oldham, J. M., Gramegna, A., Stainer, A., Mantero, M., Sverzellati, N., Lacedonia, D., Richeldi, L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02554-8 · Cited by 24
Self-citationWang, X., Gadhave, D. G., Chauhan, G., & Gupta, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105233 · Cited by 25
Huh, J.-Y., Lee, J. H., & Song, J. W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1301923 · Cited by 30
Devaraj, A., Ottink, F. A., Rennison-Jones, C., Blé, F.-X., Joly, O., Azim, A., Gerry, S., Harston, G., Ostridge, K., & George, P. M. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2274le · Cited by 27
Lin, D. C.-C., Qiao, L., Zhang, Y.-N., Liu, Y., & Liu, X. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.08.024 · Cited by 24
Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation
Warsinske, H., Ashley, S. L., Linderman, J. J., Moore, B. B., & Kirschner, D. E. (2015) · Bulletin of Mathematical Biology · doi:10.1007/s11538-015-0096-2 · Cited by 26
Fernandez, I. E., Heinzelmann, K., Verleden, S. E., & Eickelberg, O. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201410-476mg · Cited by 24
Zakrzewicz, D., Zakrzewicz, A., Didiášová, M., Korencak, M., Kosanovic, D., SCHERMULY, R. T., Markart, P., & Wygrecka, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.09.008 · Cited by 26
Madala, S. K., Thomas, G., Edukulla, R., Davidson, C. R., Schmidt, S., Schehr, A., & Hardie, W. D. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00063.2015 · Cited by 24
Fernandez, I. E., Amarie, O. V., Mutze, K., Königshoff, M., Yildirim, A. Ö., & Eickelberg, O. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00183.2015 · Cited by 24
Lian, X., Chen, X., Sun, J., An, G., Li, X., Wang, Y., Niu, P., Zhu, Z., & Tian, L. (2017) · Toxicology Research · doi:10.1039/c7tx00126f · Cited by 24
Johannson, K. A., Kolb, M. R. J., Fell, C. D., Assayag, D., Fisher, J. H., Churg, A., de Boer, K., Kelly, M. M., Lee, A. G., Leipsic, J. A., et al. (2017) · Canadian Journal of Respiratory Critical Care and Sleep Medicine · doi:10.1080/24745332.2017.1359056 · Cited by 23
Self-citationManitsopoulos, N., Nikitopoulou, I., Maniatis, N. A., Μagkou, C., Kotanidou, A. N., & Orfanos, S. E. (2017) · Respiration · doi:10.1159/000481201 · Cited by 25
Magnani, D., Lenoci, G., Balduzzi, S., Artioli, G., & Ferri, P. (2017) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v88i5-s.6870 · Cited by 25
Kokosi, M. A., Margaritopoulos, G. A., & Wells, A. U. (2018) · European Respiratory Review · doi:10.1183/16000617.0117-2017 · Cited by 24
Visual analogue scales for interstitial lung disease: a prospective validation study
Yates, H., Adamali, H. I., Maskell, N. A., Barratt, S. L., & Sharp, C. (2018) · QJM · doi:10.1093/qjmed/hcy102 · Cited by 28
Kanemaru, R., Takahashi, F., Kato, M., Mitsuishi, Y., Tajima, K., Ihara, H., Hidayat, M., Wirawan, A., Koinuma, Y., Hayakawa, D., et al. (2018) · Lung · doi:10.1007/s00408-018-0134-6 · Cited by 26
“In the pathogenesis of IPF, a possible role of TGFβ is to induce EMT in alveolar epithelial cells, and cells that have undergone EMT would contribute to the formation of fibroblastic foci and to abnormal ECM accumulation [25, 26] Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.”
BackgroundInfluentialComeglio, P., Filippi, S., Sarchielli, E., Morelli, A., Cellai, I., Corno, C., Pini, A., Adorini, L., Vannelli, G. B., Maggi, M., et al. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0913-1 · Cited by 23
Nakamura, M., Okamoto, M., Fujimoto, K., Ebata, T., Tominaga, M., Nouno, T., Zaizen, Y., Kaieda, S., Tsuda, T., Kawayama, T., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.33 · Cited by 22
Sköld, C. M., Arnheim‐Dahlström, L., Bartley, K., Janson, C., Kirchgaessler, K.-U., LEVINE, A. M., & Ferrara, G. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.06.001 · Cited by 26
Morisset, J., & Lee, J. S. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000600 · Cited by 23
“Both medications have been shown to reduce the decline of FVC by about 50% after 1 year on therapy [8,9,26].”
BackgroundNintedanib Inhibits Wnt3a-Induced Myofibroblast Activation by Suppressing the Src/β-Catenin Pathway
Li, X., Liu, X., Deng, R., Gao, S., Yu, H., Huang, K., Jiang, Q., Liu, R., Li, X., Zhang, L., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00310 · Cited by 27
“Clinical studies have shown that nintedanib improves the forced vital capacity (FVC) of patients (Richeldi et al., 2014; Kolb et al., 2017).”
BackgroundMilara, J., Ballester, B., Safont, M. J., Artigues, E., Escrivá, J., Morcillo, E. J., & Cortijo, J. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-00343-w · Cited by 24
The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis
Yombo, D. J. K., Odayar, V., Gupta, N., Jegga, A. G., & Madala, S. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645717 · Cited by 22
“Currently, the United States Food and Drug Administration (FDA) approved therapies to treat IPF, Nintedanib or Pirfenidone, slow the rate of FVC decline but do not reverse ongoing fibrosis (3, 4).”
BackgroundCottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.005 · Cited by 27
Self-citationGuidelines or guidance for better idiopathic pulmonary fibrosis management?
Behr, J. (2016) · BMC Medicine · doi:10.1186/s12916-016-0567-9 · Cited by 22
For the CleanUP-IPF Study Team, Anstrom, K. J., Noth, I., Flaherty, K. R., Edwards, R., Albright, J., Baucom, A., Brooks, M. M., Clark, A., Clausen, E. S., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-1326-1 · Cited by 25
Self-citationDrug-induced interstitial lung disease: a narrative review of a clinical conundrum
Harrison, M. L., Kavanagh, G., Corte, T. J., & Troy, L. K. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2329612 · Cited by 28
Hu, W., & Xu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375171 · Cited by 27
Macisaac, S., Somboonviboon, D., Scallan, C. J., & Kolb, M. R. J. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2340723 · Cited by 26
Self-citationCottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.018 · Cited by 25
Self-citationZhang, J., Li, Q., Shao, Q., Song, J., Zhou, B., & Shu, P. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27045 · Cited by 22
Cell Therapy in Idiopathic Pulmonary Fibrosis†
Serrano‐Mollar, A. (2018) · Medical Sciences · doi:10.3390/medsci6030064 · Cited by 27
Xu, Z., Li, H., Wen, F., Bai, C., Chen, P., Fan, F., Hu, N., Stowasser, S., & Kang, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0887-1 · Cited by 23
Self-citationLai, R.-S., Chen, C.-F., Chu, K., & Lin, M. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000201 · Cited by 22
Aronson, K. I., Hayward, B. J., Robbins, L. P., Kaner, R. J., Martínez, F. J., & Safford, M. M. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000522 · Cited by 24
Nakanishi, T., Cerani, A., Forgetta, V., Zhou, S., Allen, R. J., Leavy, O. C., Koido, M., Assayag, D., Jenkins, G. R., Wain, L. V., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.03979-2020 · Cited by 22
Khor, Y. H., Goh, N. S. L., Wong, A. W., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., et al. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202108-980oc · Cited by 23
Self-citationYang, X., Sun, W., Jing, X., Zhang, Q., Huang, H. F., & Xu, Z. (2022) · Respiratory Research · doi:10.1186/s12931-022-02012-x · Cited by 24
Hung, C., Tsai, Y.-W., Wu, Y., Yeh, C., & Yang, K. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00850-x · Cited by 22
Homma, S. A., Suda, T., Hongo, Y., Yoshida, M., Hiroi, S., Iwasaki, K., Takeshima, T., & Kondoh, Y. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.07.004 · Cited by 26
Exosomal Micro-RNAs as Intercellular Communicators in Idiopathic Pulmonary Fibrosis
Negrete-García, M. C., Ramos-Abundis, J. D. J., Alvarado‐Vásquez, N., Montes-Martínez, E., Montaño, M., Ramos, C., & Sommer, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911047 · Cited by 22
Doi, H., Atsumi, J., Baratz, D. M., & Miyamoto, Y. (2023) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2023.0014 · Cited by 24
Wang, X., Wan, W., Zhang, J., Lü, J., & Liu, P. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.042 · Cited by 23
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis
Lee, C. H., Kwak, S. H., Han, J., Shin, J. H., Yoo, B., Lee, Y. S., Park, J. S., Lim, B. J., Lee, J. G., Kim, Y. S., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00580-2023 · Cited by 25
Rao, L., Zhu, P., Guo, M., Hu, M., Guo, X., Du, Y., & Xu, G. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102298 · Cited by 24
Bridges, J. F. P., Paly, V. F., Barker, E. R., & Kervitsky, D. J. (2014) · Patient · doi:10.1007/s40271-014-0081-0 · Cited by 27
Ockham’s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer
Stella, G. M., Gentile, A., Balderacchi, A. M., Meloni, F., Milan, M., & Benvenuti, S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1008-4 · Cited by 23
Zhou, W., Zhuang, Y., Sun, J., Wang, X., Zhao, Q., Xu, L., & Wang, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-04486-y · Cited by 22
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.